Aclarion Q1 EPS Boosted by Ascendiant Capital Markets

Aclarion, Inc. (NASDAQ:ACON) – Investment analysts at Ascendiant Capital Markets lifted their Q1 2026 EPS estimates for shares of Aclarion in a report released on Wednesday, March 25th. Ascendiant Capital Markets analyst L. Ward now forecasts that the company will post earnings per share of ($1.55) for the quarter, up from their previous estimate of ($2.79). The consensus estimate for Aclarion’s current full-year earnings is ($263.33) per share. Ascendiant Capital Markets also issued estimates for Aclarion’s Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($1.00) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($4.37) EPS.

ACON has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. Wall Street Zen raised Aclarion from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Aclarion Price Performance

Shares of Aclarion stock opened at $3.27 on Monday. The firm has a 50 day simple moving average of $3.05 and a 200 day simple moving average of $5.44. Aclarion has a fifty-two week low of $2.34 and a fifty-two week high of $13.69. The firm has a market cap of $7.46 million, a P/E ratio of -0.19 and a beta of 1.44.

Aclarion (NASDAQ:ACON) last announced its earnings results on Wednesday, March 18th. The company reported ($2.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.60) by $1.59. Aclarion had a negative net margin of 9,517.11% and a negative return on equity of 52.31%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.